PHARMAID study protocol: Randomized controlled trial to assess the impact of integrated pharmaceutical care at a psychosocial intervention on caregiver's burden in Alzheimer's disease or related diseases

详细信息    查看全文

• 作者：T. Novais^a ; ^b ; ^c ; ^{teddy.novais@chu-lyon.fr} ; C. Moutet^b ; ^{claire.moutet@chu-lyon.fr} ; F. Delphin-Combe^d ; ^{floriane.delphin-combe@chu-lyon.fr} ; V. Dauphinot^d ; ^{virginie.dauphinot@chu-lyon.fr} ; C. Colin^a ; ^e ; ^f ; ^{cyrille.colin@chu-lyon.fr} ; P. Krolak-Salmon^b ; ^d ; ^e ; ^g ; ^{pierre.krolak-salmon@chu-lyon.fr} ; C. Mouchoux^b ; ^c ; ^e ; ^g ; ^{christelle.mouchoux@chu-lyon.fr} ; the PHARMAID study group
• 关键词：Pharmaceutical care ; Psychosocial intervention ; Study protocol ; Caregivers ; Burden ; Alzheimer's Disease and Related Diseases
• 刊名：Contemporary Clinical Trials
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：53
• 期：Complete
• 页码：137-142
• 全文大小：582 K
• 卷排序：53

文摘

Alzheimer's Disease and Related Diseases (ADRD) are associated with a caregiver burden that increases with the progression of the disease. Psychosocial interventions reported a moderate improvement on caregivers' burden. Patients with ADRD and their older caregivers are also exposed to a higher risk of developing drug-related problems. The main objective of the PHARMAID study is to measure the impact of personalized pharmaceutical collaborative care integrated to a multidisciplinary psychosocial program on the burden of caregivers.MethodsThe PHARMAID study is a 18-month randomized controlled trial that started in September 2016. This paper describes the study protocol. PHARMAID plans to enroll 240 dyads, i.e. ADRD patients and caregivers, whose inclusion criteria are: outpatient with mild or major neurocognitive disorders due to ADRD, living at home, receiving support from a family caregiver. Three parallel groups will compare a control group with two experimental groups: psychosocial intervention and integrated pharmaceutical care at a psychosocial intervention. The main outcome is the caregiver's burden assessed by the Zarit Burden Index at 6, 12 and 18 months.DiscussionThis is the first trial designed to assess the specific impact of the integration of pharmaceutical care in a multidisciplinary psychosocial program on the caregiver's burden. The results will inform policymakers on strategies to implement in the near future.Trial Registration number: [ClinicalTrials.gov: NCT02802371] Registered in June 2016.